CBD Life Sciences, Inc. Expands Footprint With Proposed Strategic Acquisition of Interest in Two New York Cannabis Dispensaries
CBD Life Sciences (OTC PINK:CBDL) is in advanced discussions to acquire a strategic minority interest in two state-licensed cannabis dispensaries in Upstate New York and Long Island. The targeted acquisitions have an estimated business value of $14 million. The Upstate New York dispensary is projected to open by November 1, 2024, with the Long Island location following in early 2025.
This strategic move aims to capture a share of New York's legal cannabis market, expected to exceed $4.2 billion by 2027. The company anticipates a 20% increase in annual revenue by the end of the first year of operations and a 15% increase in EBITDA following the dispensary openings. This expansion aligns with CBDL's growth strategy, focusing on key markets, revenue growth, and enhanced profitability.
CBD Life Sciences (OTC PINK:CBDL) è in avanzate trattative per acquisire una partecipazione minoritaria strategica in due dispensari di cannabis autorizzati dallo stato nello Stato di New York e a Long Island. Le acquisizioni mirate hanno un valore commerciale stimato di 14 milioni di dollari. Si prevede che il dispensario nello Stato di New York apra entro il 1° novembre 2024, mentre quello di Long Island seguirà all'inizio del 2025.
Questa mossa strategica mira a conquistare una quota del mercato legale della cannabis di New York, che si prevede supererà 4,2 miliardi di dollari entro il 2027. L'azienda prevede un aumento del 20% nei ricavi annuali entro la fine del primo anno di attività e un aumento del 15% nell'EBITDA dopo l'apertura dei dispensari. Questa espansione è in linea con la strategia di crescita di CBDL, focalizzandosi su mercati chiave, crescita dei ricavi e maggiore redditività.
CBD Life Sciences (OTC PINK:CBDL) se encuentra en avanzadas conversaciones para adquirir una participación minoritaria estratégica en dos dispensarios de cannabis con licencia estatal en el norte del estado de Nueva York y Long Island. Las adquisiciones previstas tienen un valor comercial estimado de 14 millones de dólares. Se proyecta que el dispensario del norte de Nueva York abrirá para el 1 de noviembre de 2024, y la ubicación de Long Island seguirá a principios de 2025.
Este movimiento estratégico busca capturar una parte del mercado legal de cannabis de Nueva York, que se espera supere 4.2 mil millones de dólares para 2027. La empresa anticipa un aumento del 20% en los ingresos anuales para finales del primer año de operaciones y un aumento del 15% en EBITDA tras las aperturas de los dispensarios. Esta expansión se alinea con la estrategia de crecimiento de CBDL, centrándose en mercados clave, crecimiento de ingresos y rentabilidad mejorada.
CBD Life Sciences (OTC PINK:CBDL)는 뉴욕 주 및 롱아일랜드에 있는 두 개의 주 면허 대마초 판매점에서 전략적 소수 지분을 인수하기 위한 고위급 논의를 진행하고 있습니다. 목표 인수 가격은 약 1400만 달러로 추정됩니다. 뉴욕 주의 판매점은 2024년 11월 1일까지 개장할 것으로 예상되며, 롱아일랜드의 지점은 2025년 초에 이어서 개장할 예정입니다.
이 전략적 움직임은 2027년까지 42억 달러를 초과할 것으로 예상되는 뉴욕의 합법적인 대마초 시장에서 점유율을 확보하는 것을 목표로 하고 있습니다. 회사는 첫 해 운영 종료까지 연간 수익이 20% 증가할 것을 기대하며, 판매점 개장 이후 EBITDA가 15% 증가할 것이라고 예상하고 있습니다. 이 확장은 CBDL의 성장 전략과 일치하며, 주요 시장, 수익 성장 및 수익성 향상에 중점을 두고 있습니다.
CBD Life Sciences (OTC PINK:CBDL) est en discussions avancées pour acquérir une participation minoritaire stratégique dans deux dispensaires de cannabis licenciés par l'État dans l'État de New York et à Long Island. Les acquisitions ciblées ont une valeur commerciale estimée à 14 millions de dollars. Le dispensaire dans l'État de New York devrait ouvrir d'ici le 1er novembre 2024, avec l'emplacement de Long Island suivant au début de 2025.
Ce mouvement stratégique vise à capter une part du marché légal du cannabis de New York, qui devrait dépasser 4,2 milliards de dollars d'ici 2027. L'entreprise prévoit un augmentation de 20 % du chiffre d'affaires annuel d'ici la fin de la première année d'exploitation et une augmentation de 15 % de l'EBITDA après l'ouverture des dispensaires. Cette expansion s'aligne avec la stratégie de croissance de CBDL, axée sur des marchés clés, la croissance des revenus et une rentabilité accrue.
CBD Life Sciences (OTC PINK:CBDL) befindet sich in fortgeschrittenen Gesprächen über den Erwerb einer strategischen Minderheitsbeteiligung an zwei staatlich lizenzierten Cannabis-Apotheken im Bundesstaat New York und auf Long Island. Die angestrebten Übernahmen haben einen geschätzten Geschäftsreichtum von 14 Millionen Dollar. Die Apotheke im Bundesstaat New York wird voraussichtlich am 1. November 2024 eröffnet, gefolgt von der Long Island-Standorte Anfang 2025.
Dieser strategische Schritt zielt darauf ab, einen Anteil am legalen Cannabis-Markt von New York zu gewinnen, dessen Wert bis 2027 voraussichtlich 4,2 Milliarden Dollar übersteigen wird. Das Unternehmen rechnet mit einem 20%igen Anstieg des Jahresumsatzes bis zum Ende des ersten Betriebsjahres und einem 15%igen Anstieg des EBITDA nach Eröffnung der Apotheken. Diese Expansion steht im Einklang mit der Wachstumsstrategie von CBDL, die sich auf wichtige Märkte, Umsatzwachstum und verbesserte Rentabilität konzentriert.
- Strategic acquisition of minority interest in two New York cannabis dispensaries with $14 million estimated business value
- Projected 20% increase in annual revenue by the end of the first year of operations
- Anticipated 15% increase in EBITDA following dispensary openings
- Expansion into New York's legal cannabis market, expected to exceed $4.2 billion by 2027
- Potential financial strain due to acquisition costs
- Delayed revenue impact as Long Island location not expected to open until early 2025
- Minority interest may limit control over dispensary operations and decision-making
The targeted acquisitions are estimated to have a business value of approximately
SCOTTSDALE, AZ / ACCESSWIRE / August 27, 2024 / CBD Life Sciences, Inc. (OTC PINK:CBDL), a leading innovator in the CBD industry, is pleased to announce that the company is in advanced discussions to acquire a strategic minority interest in two state-licensed cannabis dispensaries located in Upstate New York and Long Island.
This acquisition represents a significant growth milestone for CBD Life Sciences, Inc. as the company continues to expand its presence in the rapidly growing cannabis market. The dispensary in Upstate New York is projected to open its doors by November 1, 2024, with the Long Island location expected to follow in early 2025.
Strategic Expansion for Increased Market Penetration
With the legal cannabis market in New York expected to exceed
Strengthening Investor Confidence
CBD Life Sciences, Inc. has consistently demonstrated its commitment to delivering value to its shareholders. The acquisition aligns with the company's growth strategy, which focuses on expanding its footprint in key markets, increasing revenue streams, and enhancing profitability. With an anticipated
Leadership's Vision
"Our expansion into the New York cannabis market marks a pivotal moment for CBD Life Sciences, Inc.," said Lisa Nelson, President, and CEO of CBDL. "We are excited about the potential these dispensaries bring, not only in terms of revenue growth but also in solidifying our position as a key player in the cannabis industry. Our commitment to our investors remains our top priority, and we believe this acquisition will drive significant value in the coming years."
About CBD Life Sciences, Inc.
The CBD Vault Inc. is a wholly owned subsidiary of CBD Life Sciences Inc. The CBD Vault has developed and is retailing/wholesale a full line of cannabidiol based & organic products including, Delta 8 & 10 Gummy's, Full Spectrum Tinctures & Gummy's, Pain Cream, Roll-on's, Salve, Full Pet Line, Pre-Rolls, Full Line of Spa Products, Sleep & Anxiety Edibles. The CBD Vault's products can be viewed and purchased on the Company's website www.thecbdvault.com.
Follow our social media for the latest updates!
X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
IR Contact: cbdvaultaz@gmail.com
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.
Contact Information
Lisa Nelson
CEO
cbdvaultaz@gmail.com
4802091720
Related Images
|
SOURCE: CBD Life Sciences Inc.
View the original press release on accesswire.com
FAQ
What is CBD Life Sciences (CBDL) acquiring in New York?
When are the CBDL-acquired dispensaries expected to open?
What is the estimated business value of CBDL's targeted acquisitions?
How much is CBDL's annual revenue expected to increase from these acquisitions?
